Larry L. Kestin, MD

Articles by Larry L. Kestin, MD

ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent

ByJoe Yujiao Chang, MD, PhD,Larry L. Kestin, MD,R. Bryan Barriger, MD,Indrin J. Chetty, PhD,Mark E. Ginsburg, MD,Sanath Kumar, MD,Billy W. Loo, Jr, MD, PhD,Benjamin Movsas, MD,Andreas Rimner, MD,Kenneth E. Rosenzweig, MD,Thomas E. Stinchcombe, MD,Gregory M. M. Videtic, MD, CM,Henning Willers, MD

August 15th 2014

The treatment of inoperable stage III non–small-cell lung cancer (NSCLC) remains a challenge due to high rates of distant metastasis, local recurrence, and toxicity associated with definitive therapy.

Latest Updated Articles

ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent
Published: August 15th 2014 | Updated:

Larry L. Kestin, MD

Articles by Larry L. Kestin, MD

ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent

Latest Updated Articles

Trending on CGTlive®

CARsgen’s CAR-T Satri-Cel Significantly Reduces CA19-9 Levels in Patients With Pancreatic Ductal Adenocarcinoma

Around the Helix: Cell and Gene Therapy Company Updates – October 22, 2025

Guess the Therapy Answer October 23, 2025

AskBio’s Heart Failure Gene Therapy AB-1002 Shows Ability to Improve NYHA Class in Phase 1 Trial